News
Pliant Therapeutics PLRX received a positive safety review of the ongoing INTGERIS-IPF phase IIa study evaluating PLN-74809 at 320 mg for the treatment of idiopathic pulmonary fibrosis (IPF) from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback